Related Experiment Video
Updated: May 10, 2025
Production and Visualization of Bacterial Spheroplasts and Protoplasts to Characterize Antimicrobial Peptide Localization
Published on: August 11, 2018
From Bench to Bedside: A Comprehensive Study on Pardaxin Peptide's Antimicrobial Effect on Escherichia coli,
P Aminnia1, A Sharifi Niknafs1, F Doustdar1
1Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract:
Escherichia coli is a common cause of urinary tract infections and has shown increasing resistance to available antimicrobial agents. Antimicrobial peptides, such as Pardaxin, offer a potential alternative to traditional antibiotics due to their ability to disrupt bacterial cell membranes through interaction with the lipid bilayer. This mode of action reduces the likelihood of resistance development compared to conventional antibiotics that target specific cellular processes. The objective of this study was to assess the antimicrobial efficacy of the Pardaxin peptide against both standard and clinical strains of E. coli. E. coli ATCC 25922 was used as the standard strain, and 20 samples derived from patients were included in the study. Isolation and identification of E. coli were performed using enrichment media, selective media, and biochemical tests. Bacterial cultures were conducted on Mueller-Hinton agar, and the antimicrobial effect of the Pardaxin peptide was assessed using classic disk diffusion tests. During the disk diffusion test, a distinct area of no growth was observed surrounding the Pardaxin disks for both the standard and clinical strains. In the microdilution test, the minimum inhibitory concentration (MIC) of Pardaxin was found to be 390 µg/ml for the clinical strain and 450 µg/ml for the standard strain. These concentrations are comparable to the 500 µg/ml concentration of erythromycin, indicating the antibacterial properties of Pardaxin against E. coli. The results of this study provide evidence for the antimicrobial properties of the Pardaxin peptide against both standard and clinical strains of E. coli.
Insights
Pardaxin, an antimicrobial peptide, effectively inhibited both standard and clinical strains of Escherichia coli (E. coli). This peptide disrupts bacterial membranes, offering a promising alternative to antibiotics against E. coli infections.
Area of Science:
- Microbiology
- Biochemistry
- Pharmacology
Background:
- Escherichia coli (E. coli) is a leading cause of urinary tract infections, exhibiting growing resistance to conventional antibiotics.
- Antimicrobial peptides (AMPs) like Pardaxin present a novel therapeutic avenue, targeting bacterial cell membranes to circumvent resistance mechanisms.
- Pardaxin's membrane-disrupting action offers a reduced likelihood of resistance development compared to traditional antibiotics.
Purpose of the Study:
- To evaluate the antimicrobial effectiveness of the Pardaxin peptide against both reference and clinical isolates of E. coli.
- To compare Pardaxin's efficacy against E. coli with that of erythromycin.
Main Methods:
- Isolation and identification of E. coli from clinical samples using standard microbiological techniques.
- Antimicrobial activity assessment via disk diffusion and microdilution assays on Mueller-Hinton agar.
- Determination of Minimum Inhibitory Concentration (MIC) for Pardaxin against E. coli strains.
Main Results:
- Pardaxin demonstrated significant antimicrobial activity against both E. coli ATCC 25922 and clinical isolates, evidenced by clear zones of inhibition in disk diffusion tests.
- The Minimum Inhibitory Concentration (MIC) of Pardaxin was determined to be 390 µg/ml for clinical strains and 450 µg/ml for the standard strain.
- Pardaxin's efficacy was comparable to erythromycin (500 µg/ml), highlighting its potent antibacterial properties.
Conclusions:
- Pardaxin exhibits significant antimicrobial efficacy against both standard and clinical strains of E. coli.
- The study supports Pardaxin as a potential therapeutic agent for combating E. coli infections, particularly in the context of rising antibiotic resistance.
- Pardaxin's mechanism of action suggests a lower propensity for resistance development, making it a promising candidate for further investigation.
